Literature DB >> 10596368

[Neuronal potassium channel opening with flupirtine].

J Kornhuber1, M Maler, J Wiltfang, S Bleich, D Degner, E Rüther.   

Abstract

The spectrum of action of flupirtine includes analgesic, muscle-relaxant and neuroprotective properties. The substance's mechanism of action has yet to be fully explained. Over the past few years, however, evidence has accumulated that flupirtine interacts with the glutamatergic N-Methyl-D-Aspartate (NMDA) receptor. Although it was not possible to demonstrate a direct effect on the NMDA receptor, all of the findings pointed to an indirect influence on the NMDA receptor in the sense of a functional NMDA antagonism. It was thus postulated that a site of action "up- or downstream" of the NMDA receptor is influenced. Such a site of action proved to be the G-protein-activated inwardly rectifying K+ channels (GIRK), the opening of which leads to a stabilization of the resting membrane potential of neuronal cells and thus causes an indirect inhibition of the NMDA receptor. At therapeutically relevant concentrations, flupirtine is a neuronal potassium channel opener. This mechanism may explain the spectrum of action of flupirtine. Selective neuronal potassium channel opening (SNEPCO) thus proves to be a new principle of action, making flupirtine the prototype of a new substance class with analgesic, muscle-relaxant and neuroprotective properties. The experimental basis for this working hypothesis and the resulting model concepts are presented from the perspective of a four-stage approach.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596368     DOI: 10.1055/s-2007-994997

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  6 in total

1.  Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine.

Authors:  Felicia Klinger; Petra Geier; Mario M Dorostkar; Giri K Chandaka; Arsalan Yousuf; Isabella Salzer; Helmut Kubista; Stefan Boehm
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  Flupirtine in pain management: pharmacological properties and clinical use.

Authors:  Jacques Devulder
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

3.  Carba Analogues of Flupirtine and Retigabine with Improved Oxidation Resistance and Reduced Risk of Quinoid Metabolite Formation.

Authors:  Konrad W Wurm; Frieda-Marie Bartz; Lukas Schulig; Anja Bodtke; Patrick J Bednarski; Andreas Link
Journal:  ChemMedChem       Date:  2022-07-07       Impact factor: 3.540

4.  Flupirtine: Clinical pharmacology.

Authors:  S Harish; K Bhuvana; Girish M Bengalorkar; Tn Kumar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-04

5.  Comparative evaluation of oral flupirtine and oral diclofenac sodium for analgesia and adverse effects in elective abdominal surgeries.

Authors:  Joginder Pal Attri; Gagandeep Kaur Sandhu; Sudhir Khichy; Harsimrat Singh; Kulwinder Singh; Radhe Sharan
Journal:  Anesth Essays Res       Date:  2015 Jan-Apr

6.  Flupirtine in the Management of Taxane-induced Pain in Cancer Patients.

Authors:  Anusha Paul; M Abdul Razak; Ameya Binoy; Padma Uma Devi; Keechilat Pavithran
Journal:  Indian J Palliat Care       Date:  2021-10-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.